Granules India Limited
NSE GRANULES.NS
Granules India Limited EBIT for the year ending March 31, 2024: USD 74.21 M
-
Granules India Limited EBIT for the year ending March 31, 2023 was USD 90.41 M, a 18.12% change year over year.
-
Granules India Limited EBIT for the year ending March 31, 2022 was USD 76.55 M, a -23.29% change year over year.
-
Granules India Limited EBIT for the year ending March 31, 2021 was USD 99.78 M, a 66.12% change year over year.
-
Granules India Limited EBIT for the year ending March 31, 2020 was USD 60.07 M, a 36.76% change year over year.
| Date | EBIT | EBITDA | Net Income | EPS (Diluted) |
|---|
| CEO | Dr. Kandiraju Venkata Sita Ram Rao B.Tech, M.E., Ph.D. |
| IPO Date | June 20, 2005 |
| Location | India |
| Headquarters | My Home Hub |
| Employees | 4,057 |
| Sector | Health Care |
| Industries | |
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, Africa, the Middle East, and internationally. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers various FDs, such as tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; and other specialty products for oncology. The Company also exports its products. Granules India Limited was founded in 1984 and is based in Hyderabad, India.
Past 5 years
USD 18.35
USD 13.57
USD 11.66
USD 6.56
USD 17.52
StockViz Staff
January 15, 2025
Any question? Send us an email